InnoCare Pharma has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover and develop new medicines, the companies announced September 24, 2026.¹ InnoCare will leverage its proprietary drug discovery platform to discover and advance compounds against up to 5 targets addressing critical unmet medical needs, with Lilly responsible for subsequent development and commercialization.¹
Key facts
- Companies: InnoCare Pharma; Eli Lilly and Company
- Deal scope: Compounds against up to 5 targets
- Deal terms: Up to $100 million upfront/near-term; up to $3.25 billion in milestones
- Combined potential value: ~$3.35 billion, plus tiered royalties
- Disclosed targets: Not disclosed
- InnoCare pipeline: 3 approved drugs; 10+ candidates in clinical development
- Recent milestone: ICP-B381 (bispecific ADC) cleared for clinical trials in China (September 2026)
- Lilly context: Similar deal structure to Lilly's August 2026 Amplitude Therapeutics collaboration
- Geography: China-based InnoCare; global Lilly partnership
"We are excited to leverage our R&D platform to collaborate with a global pharmaceutical leader like Lilly," said Jasmine Cui, PharmD, co-founder, chairwoman, and CEO of InnoCare, in a company press release.¹ "We are dedicated to expanding our partnership and innovation footprint."
What are the terms of the deal?
Under the agreement, InnoCare is eligible to receive up to $100 million in upfront and near-term payments, plus up to approximately $3.25 billion in development and commercial milestone payments, for a combined potential deal value of roughly $3.35 billion, along with single-digit tiered royalties on annual net product sales.¹ Financial terms beyond these figures, including specific initial disease targets, were not disclosed.¹
How does this deal fit into Lilly's broader business development strategy?
The InnoCare agreement follows a similar structure to other recent Lilly research collaborations with smaller biotechs, in which the partner leads early-stage target discovery and optimization while Lilly assumes responsibility for later-stage development, manufacturing, and commercialization.² In August 2026, for example, Lilly entered a comparable strategic research collaboration and licensing agreement with Amplitude Therapeutics to discover and develop trans-amplifying RNA vaccine candidates for infectious diseases, under which Amplitude leads early platform optimization before candidates advance into Lilly-led development.²
Speaking more broadly about why such structured collaborations have become central to biopharma R&D, Manisha P. Desai, PhD, senior vice president of product development at Bristol Myers Squibb, stated in a previous interview with BioPharm International®, an Industry Sciences 1 brand, "I think early alignment is very critical because development and manufacturing teams ... bring complementary sets of expertise to the table."³ As modalities grow more complex, no single organization can sustain all required capabilities in-house, Dr Desai noted, driving companies toward specialized partners that combine internal expertise with external technology and large-scale experience across many portfolios.³
